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Abstract
For designing, monitoring and analyzing a longitudinal study with an event time as
the outcome variable, the restricted mean event time (RMET) is an easily interpretable,
clinically meaningful summary of the survival function in the presence of censoring.
The RMET is the average of all potential event times measured up to a time point τ,
which can be estimated consistently by the area under the Kaplan-Meier curve over
[0, τ ]. In this paper, we present inference procedures for model-free parameters based
on RMETs under the one- and two-sample settings. We then propose a new regression
model, which relates the RMET to its covariates directly for predicting the subjectspecific RMETs. Since the standard Cox and the accelerated failure time models can
also be used for estimating such RMETs, we utilize a cross validation procedure to
select the “best” working model. Lastly we draw inferences for the subject-specific
RMETs based on the final candidate model using an independent data set or a “holdout” sample from the original data set. All the proposals are illustrated with the data
from the a HIV clinical trial conducted by the AIDS Clinical Trials Group and the
PBC study conducted by the Mayo Clinic.
Keywords: Accelerated failure time model; Cox model; cross validation, hold-out
sample, personalized medicine; perturbation-resampling method
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1

Introduction

For a longitudinal study with time T to a speciﬁc event as the primary outcome variable,
commonly used summary measures for the distribution of T are the mean, median or t-year
event rate. Due to potential censoring for T , the mean may not be well estimated. If the
censoring is heavy, the median cannot be identiﬁed empirically either. The t−year survival
rate may not be suitable for summarizing the global proﬁle of T . On the other hand, based
on the design of the study and clinical considerations, one may pre-specify a time point τ
and utilize the expected value µ of Y = min(T, τ ), the so-called restricted mean event time
(RMET), as a summary parameter. This parameter is the mean of T for all potential study
patients followed up to time τ , which has a heuristic and clinically meaningful interpretation
(Irwin, 1949; Karrison, 1987; Zucker, 1998; Murray & Tsiatis, 1999; Chen & Tsiatis, 2001;
Andersen et al., 2004; Zhang & Schaubel, 2011; Royston & Parmar, 2011; Zhao et al., 2012).
Moreover, this model-free parameter can be estimated consistently via the standard KaplanMeier (KM) curve, that is, the area under the curve up to τ. Inferences about the RMET
can be obtained accordingly.
For a study for comparing two groups, say, A and B, with event time observations,
practitioners routinely use the hazard ratio to quantify the between-group diﬀerence. When
the proportional hazards assumption is not valid, the standard maximum partial likelihood
estimator of the hazard ratio approximates a parameter which is diﬃcult, if not impossible,
to interpret as the treatment contrast (Kalbﬂeisch & Prentice, 1981; Lin & Wei, 1989; Xu
& O’Quigley, 2000; Rudser et al., 2012). Moreover, this parameter depends, oddly, on the
nuisance, study-speciﬁc censoring distributions. It follows that the hazard ratio estimators
at the interim and ﬁnal analyses from the same study or estimators from independent studies
with an identical study population would estimate diﬀerent, uninterpretable parameters due
to diﬀerential follow-up patterns. In fact, any model-based estimate in survival analysis may
have this problem. Therefore, it is highly desirable to consider an estimable, model-free
and censoring-independent parameter to quantify the treatment diﬀerence for coherent and
2
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consistent assessments between interim and ﬁnal analyses within a study, as well as across
independent studies. Model-free parameters for the treatment diﬀerence can be constructed
via two RMETs, say, µA and µB . As an example, to evaluate the added value of a potent
protease inhibitor, indinavir, for HIV patients, a pivotal study ACTG 320 was conducted
by the AIDS Clinical Trials Group (ACTG). This randomized, double-blind study (Hammer
et al., 1997) compared a three-drug combination, indinavir, zidovudine and lamivudine, with
the standard two-drug combination, zidovudine and lamivudine. There were 1156 patients
enrolled for the study. One of the endpoints was the time to AIDS or death with the followup time about one year for each patient. Figure 1 presents the Kaplan-Meier curves for
these two treatment groups. The hazard ratio estimate is 0.50 and the corresponding 0.95
conﬁdence interval is (0.33, 0.76) with a p-value of 0.001. It is not clear if the proportional
hazard assumption is valid for this study. With τ = 300 days, the estimated RMET (the area
under the KM curve up to 300 days) was 277 days for the control and was 288 days for the
three-drug combination. The estimated diﬀerence with respect to the RMET is 11 days with
the corresponding 0.95 conﬁdence interval of (3.2, 17.3) and a p-value of 0.005. Although
the treatment eﬃcacy for the three drug combination is highly statistically signiﬁcant, its
clinical beneﬁt is debatable, considering the relatively short follow-up time of the study. On
the other hand, if we mimic the concept of the hazard ratio or relative risk as a summary
measure for the treatment contrast, one may consider a model-free ratio R of (τ − µB ) and
(τ − µA ). With the above HIV data, if B is the new treatment with three drug combination,
the estimated R is 0.55 with a p-value of 9.3×10−6 , also an impressive statistically signiﬁcant
result. For a single arm, (τ − µ) is the average of the days lost from the healthy state up to
τ, a meaningful alternative to µ as a summary parameter for the distribution of T. Note that
the above conﬁdence interval estimates and p-values were obtained using a perturbationresampling method detailed in Section 2.
In this paper, we ﬁrst present the inference procedures for one- and two-sample problems
and then consider regression models for the RMET. For the regression analysis, our goal
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is to build a prediction model via an extensive model selection process to stratify future
patients using the patients’ “baseline” covariates. The existing regression models such as
the Cox model can be candidates to create such a stratiﬁcation system. However, it seems
more natural to model the RMET with the covariates directly, not via the hazard function
(Andersen et al., 2004). In this article, we consider a new class of models which takes
this approach and study the properties of the corresponding inference procedures. Since
it is unlikely that any model will be precisely correct, our ultimate goal is to choose the
best “ﬁtted” model to stratify the future patients. To avoid overly optimistic results, we
randomly split the data set into two pieces. Based on the ﬁrst piece, called the training
set, we utilize a cross validation procedure to build and select the ﬁnal model. We then use
the second data set, called the holdout set, to make inferences about the RMETs over a
range of scores created from the ﬁnal model. We use a data set from a well-known clinical
study conducted at Mayo Clinic (Therneau & Grambsch, 2000) for treating a liver disease
to illustrate the proposals for individualized prediction.

2

One- and two-sample inference procedures for RMET

For a typical subject with event time T , let Z be the corresponding q-dimensional baseline
covariate vector. Suppose that T is subject to right censoring by a random variable C,
which is assumed to be independent of T and Z. The observable quantities are (U, ∆, Z),
where U = min(T, C), ∆ = I(T ≤ C), and I(·) is the indicator function. The data,
{(Ui , ∆i , Zi ); i = 1, . . . , n}, consist of n independent copies of (U, ∆, Z). Suppose that for
a time point τ, pr(U ≥ τ ) > 0. The restricted survival time Y = min(T, τ ) may also be
censored, but its expected value µ is estimable. Let Yi be the corresponding Y for the ith
subject, i = 1, . . . , n. A natural estimator for µ is
∫
µ̂ =

τ

Ŝ(u)du,
0
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where Ŝ(u) is the KM estimator for the survival function of T based on {(Ui , ∆i ), i =
1, . . . , n}. Alternatively, one may employ the inverse probability censoring weighting method
to estimate µ as
µ̃ = n−1

n
∑
˜i
∆

Ĝ(Yi )

i=1

Yi ,

˜ i = I(Yi ≤ Ci ) and Ĝ(·) is the KM estimator of the censoring time C based on
where ∆
{(Ui , 1 − ∆i ), i = 1, . . . , n}. In Appendix A we show that µ̃ and µ̂ are asymptotically equivalent at the root n rate. Similar observations had been made by Satten & Datta (2001) with
respect to KM estimator and its inverse weighting counterpart. It is straightforward to show
that as n → ∞, n1/2 (µ̂ − µ) is approximately normal with mean zero and variance σ 2 , which
can be estimated analytically or by a perturbation-resampling method. Speciﬁcally, let
∗

µ =n

−1

n
∑
i=1

˜i
∆
Yi Qi ,
G∗ (Yi )

where {Q1 , · · · , Qn } are positive random variables with unit mean and variance and independent of the observed data and G∗ (·) is a perturbed version of the KM estimator of the
censoring variable. Here,
(

1∑
G∗ (t) = Ĝ(t) 1 −
n i=1
M̂iC (u) = I(Ui ≤ u)(1−∆i )−

∫u
0

n

∫
0

t

dM̂iC (u)
∑n
Qi
j=1 I(Uj ≥ u)

)
,

I(Ui ≥ s)dΛ̂C (s) and Λ̂C (v) is the Nelson-Aalen estimator for

the cumulative hazard function of the censoring time C. Then given the data, the conditional
distribution of n1/2 (µ∗ − µ̂) converges to the unconditional limiting distribution of n1/2 (µ̂−µ).
In practice, one may generate a large number, say, M, of replications of {Q1 , · · · , Qn } and
calculate the corresponding µ∗ . Then the empirical distribution of M generated µ∗ s can
be used to make inference about µ. This resampling technique has been used for various
applications in survival analysis and in general preforms better than its analytical counterpart
(Tian et al., 2005; Uno et al., 2007; Li et al., 2011). Moreover, if we are interested in a function
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of µ, say, g1 (µ), one can utilize M realizations of g1 (µ∗ ) for making inference. Note that for
censored data, the standard bootstrapping method may generate a KM curve which is not
deﬁned at time τ and µ would not be estimable via this bootstrap sample.
For the two-sample problem, let Z be A or B as in the Introduction. Let the corresponding means µ be denoted by µA and µB and their estimators by µ̂A and µ̂B , respectively.
Suppose we are interested in estimating a model-free parameter ζ = g2 (µA , µB ), where
g2 (·, ·) is a smooth bivariate function. For example, g2 (a, b) = b − a, b/a, (τ − a)/(τ − b) or
{b/(τ − b)}/{a/(τ − a)}. Then ζ can be estimated consistently with ζ̂ = g2 (µ̂A , µ̂B ) and its
variance estimate can be obtained via the delta-method. Alternatively, the distribution of
(ζ̂ −ζ) can be approximated by the conditional distribution of (ζ ∗ − ζ̂), where ζ ∗ = g2 (µ∗A , µ∗B )
and µ∗A and µ∗B are the perturbed µ∗ for groups A and B, respectively. The 0.95 conﬁdence
interval estimates and p-values for the HIV example in the Introduction were obtained with
M = 1000 and Qs generated from the unit exponential.

3

Regression Models for RMET

If the parameter of interest is the RMET, it is natural to model

µ(z) = E(Y |Z = z)

with the covariate vector Z = z directly (Andersen et al., 2004). For example, one may
consider
η{µ(z)} = β ′ X,

(1)

where η(·) is a given smooth, strictly increasing function from [0, τ ] to the real line, β is
a (q + 1)-dimension unknown vector and X ′ = (1, Z ′ ). A special link function is η(a) =
log{a/(τ − a)}, which mimics the logistic regression. Note that with this speciﬁc link, for
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the two sample problem, the regression coeﬃcient of the treatment indicator is
{
log

µB (τ − µA )
µA (τ − µB )

}
,

an odds-ratio like summary for the group contrast, which was used for analyzing HIV data
discussed in the Introduction.
For the general link function η(·), following the least squares principle, an inverse probability censoring weighted estimating function of β is

Sn (β) = n

−1

n
∑
˜i
∆
i=1

Ĝ(Yi )

{
}
Xi Yi − η −1 (β ′ Xi ) .

Let β̂ be the unique root of Sn (β) = 0. Under mild regularity conditions, one can show that
Sn (β) uniformly converges to a monotone limiting function
[ {
}]
S(β) = E X µ(Z) − η −1 (β ′ X)

in probability. Let β̄ be the root of S(β) = 0. It follows that β̂ converges to β̄ in probability,
even when the model is misspeciﬁed. As n → ∞, n1/2 (β̂ − β̄) converges weakly to a mean zero
Gaussian distribution. Moreover, we can make statistical inference for β̄ via the perturbationresampling methods similar to those given in the previous section. Speciﬁcally, let β ∗ be the
root of the perturbed estimating equation

n

−1

n
∑

˜i
∆

i=1

Ĝ∗ (Yi )

{
}
Xi Yi − η −1 (β ′ Xi ) Qi = 0.

It follows from the argument similar to that in Lin et al. (1993), Park & Wei (2003), and
Tian et al. (2005) that the conditional distribution of n1/2 (β ∗ − β̂) given the observed data
can approximate the unconditional limiting distribution of n1/2 (β̂ − β̄). In Appendix B, we
justify this large sample approximation.
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Note that Andersen et al. (2005) studied models such as (1) via a log-link η(·) using
a psedo-observation technique to make inferences about the regression coeﬃcient assuming
the model is correctly speciﬁed. It can be shown that in general our estimator β̂ would
converge to the same parameter as that with the procedure taken by Andersen et al. (2005)
when the model (1) is correctly specified. It would be theoretically interesting to compare the
eﬃciency of these two procedures with respect to the estimation of the regression coeﬃcients.
However, since it is unlikely that the working model would be correctly speciﬁed, in practice
it seems more relevant to evaluate such a model from the prediction point of view as we do
in this article.
Using the above model, one may estimate µ(z) by µ̂(z) = η −1 (β̂ ′ x), for any ﬁxed Z = z,
where x′ = (1, z ′ ). The distribution of {µ̂(z) − η −1 (β̄ ′ x)} can be approximated by the above
resampling method. Note that µ(z) can also be estimated via, for example, a Cox model
(Cox, 1972). Speciﬁcally, let the hazard function for given z be
′

λ(t|Z = z) = λ0 (t)eγ z ,

where γ is a q-dimensional unknown vector and λ0 (·) is the nuisance baseline hazard function.
It follows that µ(z) can be estimated by
∫

τ

′

exp{−Λ̂0 (s)eγ̂ z }ds,

µ̂(z) =
0

where γ̂ and Λ̂0 (s) are the maximum partial likelihood estimator for γ and the Breslow
∫s
estimator for Λ0 (s) = 0 λ0 (v)dv, respectively.
Alternatively, one may use the accelerated failure time (AFT) model (Kalbﬂeisch &
Prentice, 2002)
log(T ) = γ ′ Z + ϵ,
to make inference about µ(z), where γ is a q-dimensional unknown vector and ϵ is the error
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term whose distribution is entirely unspeciﬁed. Here, γ can be estimated via a rank-based
estimating function (Ritov, 1990; Tsiatis, 1990; Wei et al., 1990; Jin et al., 2003). Let γ̂
be the corresponding estimator for γ. One may estimate the survival function of eϵ by KM
′

estimator based on the data {(Ui e−γ̂ Zi , ∆i ), i = 1, · · · , n}. Let the resulting estimator be
∫τ
′
denoted by Ŝ0 (·). Then one can estimate µ(z) by µ̂(z) = 0 Ŝ0 (e−γ̂ z s)ds. Note that when
′

pr(C > eγ Z sup eϵ ) > 0, µ̂(z) is estimable for any given covariate z. In practice, we can always
′

set the censoring indicator at one for the observation with the largest Ui e−γ̂ Zi in estimating
the survival function of eϵ . Although these estimators for µ(z) may not be consistent and
in general depend on the censoring distribution under misspeciﬁed model, they still can be
reasonable predictions for the RMET.

4

Model Selection and Evaluation

All the models for estimating µ(z) discussed in the previous section are approximations to
the true model. To compare these models, one may compare the observed restricted event
time Y with the covariate vector z and its predicted µ̂(z). A reasonable predicted error
measure is E|Y − µ̂(Z)|, where the expected value is with respect to the data and the future
subject’s (Y, Z). If there is no censoring, the empirical apparent prediction error is

n

−1

n
∑

|Yi − µ̂(Zi )|,

i=1

which is obtained by ﬁrst using the entire data to compute µ̂(·) and then using the same
data to estimate the predicted error. Such an estimator may be biased downward (Stone,
1974; Geisser, 1975). An alternative is to utilize a cross-validation procedure to estimate
such a predicted error (Tian et al., 2007; Uno et al., 2007).
Speciﬁcally, consider a class of models for µ(Z). For each model, we randomly split the
data set into K disjoint subsets of approximately equal sizes, denoted by {Ik , k = 1, . . . , K}.
For each k, we use all observations which are not in Ik to obtain a model-based prediction
9
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rule µ̂(−k) (Z) for Y , and then estimate the total absolute prediction error for observations
in Ik by
D̂k =

∑ ∆
˜j
j∈Ik

Then we use the average n−1

∑K
k=1

Ĝ(Yj )

Yj − µ̂(−k) (Zj ) .

D̂k as a K-fold cross-validation estimate for the absolute

prediction error. We may repeat the aforementioned procedure a large number of, say B,
times with diﬀerent random partitions. Then the average of the resulting B cross-validated
estimates is the ﬁnal B random K-fold cross-validation estimate for the absolute prediction
error of the ﬁtted regression model. Generally, the model which yields the smallest crossvalidated absolute prediction error estimate among all candidate models is chosen as the ﬁnal
model. On the other hand, a parsimonious model may be chosen if its empirical predicted
error is comparable with that for the best one. We then reﬁt the entire data set with this
selected model for making predictions based on µ̂(·).
Note that in the training stage of this cross validation process, a candidate model may be
obtained via a complex variable selection process. For example, a Cox model may be built
with a stepwise regression or lasso procedure. In this case, the ﬁnal choice for creating the
score would be reﬁtting the entire data set with the selected model building algorithm.

5

Nonparametric Inference About Subject-Specific RMET

Now, let the observed µ̂(·) from the ﬁnal selected model be denoted by µ̂opt (·) and for a future
subject with (Y, Z), let its prediction score be denoted by V = µ̂opt (Z). That is, for each
future subject, the covariate vector Z is reduced to a one-dimensional V which is a function
of Z. If the selected model is close to the true one, we expect that E(Y |V ) ≈ µ(Z) ≈ V.
In general, however the group mean ξ(v) = E(Y |V = v) by clustering all subjects with
Z, whose µ̂opt (Z) = v, may be quite diﬀerent from the identity function. Therefore, the
conventional parametric inferences for predicting ξ(v) via the selected model may not be
valid. On the other hand, since we reduce the covariate information to a univariate score V,
10
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one may utilize a nonparametric estimation procedure to draw valid inferences about ξ(·).
To make nonparametric inference about ξ(v) simultaneously across a range of the score
v, we use a fresh independent data set or “hold-out” set from the original data set. With
slight abuse of notations, let such a fresh data set be denoted by {(Ui , ∆i , Vi ), i = 1, · · · , n}.
We propose to use local linear smoothing method to estimate ξ(v) nonparametrically. To
this end, for a score v inside the support of V , let â and b̂ be the solution of the estimating
equation

Sn (a, b; v) =

n
∑
i=1



˜i  1 [
]
Kh (Vi − v)∆
−1

 Yi − η̃ {a + b(Vi − v)} = 0,
Ĝ(Yi |v)
Vi − v

where K(·) is a smooth symmetric kernel function with a ﬁnite support, Kh (s) = K(s/h)/h,
h = op (1) is the smoothing bandwidth,
{
Ĝ(t|v) = exp −

n ∫
∑
i=1

0

t

dN C (u)Kh (Vi − v)
∑n i
j=1 (Uj ≥ u)Kh (Vj − v)

}

is the local nonparametric estimator for the survival function of C (Dabrowska, 1987, 1989)
˜ i ). Here η̃(·) is a strictly increasing function from
and NiC (u) = I(min(Ui , τ ) ≤ u)(1 − ∆
[0, τ ] to the entire real line given a priori. The resulting local linear estimator for ξ(v)
ˆ
ˆ − ξ(v)} converges weakly
is ξ(v)
= η̃ −1 (â). As n → ∞ and nh5 = op (1), (nh)1/2 {ξ(v)
to a mean zero Gaussian. The details are given in Appendix C. Since the censoring time
C is assumed to be independent of V, generally the nonparametric KM estimator based
on entire sample is used in the inverse probability weighting method for Sn (a, b; v). Here,
we use the local estimator Ĝ(t|v) in the above estimating equation. In the Appendix C,
we show that this estimation procedure results in a more accurate estimator for ξ(v) than
that using Ĝ(·). Note that when the empirical distribution of {Vi , i = 1, · · · , m} is quite
non-uniform, transforming the score via an appropriate function before smoothing could
potentially improve the performance of the kernel estimation (Wand et al., 1991; Park et al.,
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1997; Cai et al., 2010).
The aforementioned perturbation-resampling procedure in section 2 can be used to esˆ
timate the variance of ξ(v).
To this end, let â∗ and b̂∗ be the solution of the perturbed
estimating equation



Sn∗ (a, b; v) =

n
∑
i=1

where

Qi

˜i  1 [
]
Kh (Vi − v)∆
−1
 Yi − η̃ {a + b(Vi − v)} = 0,

∗
G (Yi |v)
Vi − v
{

G∗ (t|v) = exp −

n ∫
∑
i=1

t
0

Q dN C (u)Kh (Vi − v)
∑n i i
j=1 Qj (Uj ≥ u)Kh (Vj − v)

}
.

Then a perturbed estimator for ξ(v) is ξˆ∗ (v) = η̃ −1 (â∗ ). Conditional on the observed data,
ˆ
the limiting distribution of (nh)1/2 {ξˆ∗ (v)− ξ(v)}
approximates the unconditional counterpart
ˆ − ξ(v)}. It follows that one can estimate the variance of ξ(v)
ˆ
of (nh)1/2 {ξ(v)
by σ̂ 2 (v), the
empirical variance of M realized ξˆ∗ (v)′ s. Based on generated ξˆ∗ (v), one may construct
(1 − 2α) conﬁdence interval of ξ(v) as
[
]
ˆ − cα σ̂(v), ξ(v)
ˆ + cα σ̂(v) ,
ξ(v)

where cα is the upper 100α percentage point of the standard normal.
ˆ does not converge weakly
It is important to note that as a process, the standardized ξ(·)
to a tight process (Bickel & Rosenblatt, 1973). On the other hand, one can use the strong
approximation theory to show that the distribution of the supremum of the standardized
process can still be approximated by that of the supremum of its perturbed counterpart
(Gilbert et al., 2002). It follows that for an interval [v1 , v2 ], a subset of the support of V, the
(1 − 2α) simultaneous conﬁdence band of ξ(v), v ∈ [v1 , v2 ] can be constructed similarly as
ˆ − dα σ̂(v), ξ(v)
ˆ + dα σ̂(v)],
[ξ(v)

12
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where

{

ˆ
|ξˆ∗ (v) − ξ(v)|
pr
< dα (Ui , ∆i , Vi ), i = 1, . . . , n
sup
σ̂(v)
v∈[v1 ,v2 ]

}
= 1 − 2α,

where [v1 , v2 ] is an interval within the support of V. Since we require that the bandwidth h
ˆ
converges to zero at a rate faster than the “optimal” Op (n−1/5 ) rate, the bias of ξ(v)
does
not play any role in the construction of the conﬁdence interval or band for ξ(v).
As with any nonparametric function estimation problem, it is crucial to choose an appropriate bandwidth h in order to make proper inference about ξ(v). Here, we propose a
L fold cross-validation procedure to choose an optimal h value which minimizes a weighted
cross-validated absolute prediction error. To this end, we randomly split the data set into L
disjoint subsets of approximately equal sizes, denoted by {Il , l = 1, . . . , L}. For any ﬁxed h,
we use all observations which are not in Il to obtain an estimator ξˆ(−l) (v, h) for predicting
Y , and then estimate the total absolute prediction errors based on observations in Il by

D̂l (h) =

∑ ∆
˜j
j∈Il

Then we may use D̂(h) = n−1

∑L
l=1

Ĝ(Yj )

Yj − ξˆ(−l) (Vj , h) .

D̂l (h) as a ﬁnal estimate for the absolute prediction

error. We may choose hopt as the minimizer of D̂(h). In practice, to reduce the asymptotic
bias, we propose to use a bandwidth slightly smaller than hopt , which is expected to be in the
order of Op (n−1/5 ). For example, h = hopt × n−0.05 can be used in local smoothing estimation
(Tian et al., 2005; Cai et al., 2010).

6

Example for Subject-Specific Prediction

In this section, we use a well-known data set from a liver study to illustrate how to build
and select a model, and make inferences simultaneously about the RMETs over a range
of scores created by the ﬁnal model. This liver disease study in primary biliary cirrhosis
(PBC) was conducted between 1974 and 1984 to evaluate the drug D-penicillamine, which
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was found to be futile with respect to the patient’s mortality. The investigators for the study
then used this rich data set to build a prediction model with respect to mortality (Fleming
& Harrington, 1991). There were a total of 418 patients involved in the study including
112 patients who did not participate in the clinical trials, but had baseline and mortality
information. For illustration, any missing baseline value was imputed by the corresponding
sample mean calculated from its observed counterparts in the study. We randomly split the
data set with equal sizes as the training and hold-out sets.
For our analysis, we consider sixteen baseline covariates: gender, histological stage of the
disease (1, 2, 3, and 4), presence of ascites, edema, hepatomegaly or enlarged liver, blood
vessel malformations in the skin, log-transformed age, serum albumin, alkaline phosphotase,
aspartate aminotransferase, serum bilirubin, serum cholesterol, urine copper, platelet count,
standardized blood clotting time and triglycerides. Three models discussed in Section 4
with these covariates included additively were considered in the model selection. They are
the Cox model, the AFT model, and the new RMET model. Moreover, since a Cox model
with ﬁve speciﬁc covariates (edema, age, bilirubin, albumin and standardized blood clotting
time) has been established as a prediction model in the literature (Fleming & Harrington,
1991), we also considered the aforementioned three types of models with these ﬁve covariates
additively in our analysis. There are, therefore, six diﬀerent models were considered. Note
that there was no variable selection procedure involved in the model building stage for this
illustration.
Figure 2 shows the KM curve for the patients’ survival with the entire data set. The
patients’ follow-up times are up to 13 years. Since the tail part of the KM estimate is not
stable. We let τ = 10 years for illustration. The overall 10-year survival rate is about 44%.
Table 1 presents the L1 prediction error estimates for the RMET up to 10 years for the
three model building procedures based on 100 random 5-fold cross-validations. With crossvalidation, the L1 prediction error is minimized at 1.94 when the proposed regression model
(1) with the logistic link function η(µ) = log{µ/(τ − µ)} based on ﬁve baseline covariates is
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utilized.
The ﬁnal model is obtained by ﬁtting the RMET model with ﬁve covariates:

η{µ(z)} = 6.36 − 0.14 × edema − 2.95 × log(age) + 0.99 × log(bilirubin)
−0.35 × log(albumin) + 0.34 × log(clotting time).
We then use the score created by this model to make prediction and stratiﬁcation for subjects
in the hold-out set.
For predicting future restricted event time, we use the procedures proposed in Section 5
to estimate the subject-speciﬁc RMET ξ(v) over a range of score v’s, and construct its 0.95
pointwise and simultaneous conﬁdence intervals over the interval [0.07, 9.52], where 0.07 and
9.52 are the 2nd and 98th percentiles of observed scores in the holdout set. Here, we let
K(·) be the Epanechnikov kernel and the bandwidth be 2.1, as selected via cross-validation.
The results are presented in the ﬁrst panel of Figure 3. For comparison, we also present
the corresponding results in the second panel of Figure 3 with the survival function of the
censoring time C being estimated based on the entire sample rather than locally as proposed
in Section 5. As expected, the resulting estimator for ξ(v) is less accurate, e.g., the 95%
conﬁdence interval for ξ(5) is 24.8% wider when the survival function of C is estimated based
on the entire sample.
As a conventional practice, we may stratify the subjects in the hold-out set into groups
such as low, intermediate and high risk groups by discretizing the continuous score. For
example, we may create four classes based on the quartiles of the scores. Figure 4 presents
the KM curves for these four strata. Visually these curves appear quite diﬀerent. Moreover,
their estimated RMETs and the standard error estimates (in paratheses) are 3.59 (0.46), 6.26
(0.53), 8.50 (0.40), and 9.14 (0.31) in years, respectively. These indicate that the scoring
system does have reasonable discriminating capability with respect to the patients’ RMET.
How to construct an “eﬃcient” categorization of the existing scoring system warrants future
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research.

7

Remarks

In comparing two groups with censored event time data, the point and interval estimates of
the two RMETs and their counterparts for the group contrast provide much more clinically
relevant information than, for example, the hazard ratio estimate. The results from the HIV
data set from ACTG 320 discussed in the Introduction is a good example, in that the three
drug combination is statistically signiﬁcantly better than the conventional therapy, but the
gain from the new treatment with respect to RMET was not as impressive from a clinical
standpoint, likely due to the relatively short follow-up time. Note that for this case, the
median event time cannot be estimated empirically due to heavy censoring. Moreover, we
cannot evaluate models using the individual predicted error, such as the L1 distance function,
with the median event time. It follows that the RMET is probably the most meaningful,
model-free, global measure for the distribution of the event time to evaluate the treatment
eﬃcacy. The choice of τ to deﬁne the RMET is crucial, which may be determined at the
study design stage with respect to clinical relevance and feasibility of conducting the study.
Note that one of the attractive features of the model which directly relates the RMET
to its covariates proposed here is that the score created is free of the censoring distribution
even when the model is not correctly speciﬁed. On the other hand, those scores built from
the Cox or AFT models depend on the study-speciﬁc censoring distribution when the model
is misspeciﬁed.

Appendix A: The asymptotic equivalence of µ̂ and µ̃
Firstly, for t ∈ [0, τ ], the KM estimator Ŝ(t) is the solution to the forward integral equation
∫

t

S(t) = 1 −

S(u− )dΛ̂(u)

0
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and thus
∫

∫
1 t dN (u)
dN (u)
Ŝ(t) = 1 −
Ŝ(u )
=1−
+ op (n−1/2 )
−
Y
(u)
n
0 Ĝ( u )
0
n
n
˜i
˜i
1 ∑ I(Yi ≤ t)∆
1 ∑ I(Yi > t)∆
−1/2
=1−
+ op (n
)=
+ op (n−1/2 )
n i=1
n i=1
Ĝ(Yi )
Ĝ(Yi )
where N (t) =

∑n
i=1

t

−

∑n

Ni (t), Y (t) =

i=1

I(Ui ≥ t) and Λ̂(·) is the Nelsen-Aalen estimator of

the cumulative hazard function of Y. In the above derivation, we have used the fact that
n−1 Y (t) = Ĝ(t− )Ŝ(t− ) + op (n−1 ).

Therefore
1∑
µ̂ − µ̃ =
n i=1
n

1
n

=

∫

˜i
I(Yi > t)∆

τ

Ĝ(Yi )

0

n
∑

˜i
∆

i=1

Ĝ(Yi )

dt − µ̃ + op (n−1/2 )

Yi − µ̃ + op (n−1/2 ) = op (n−1/2 ).

Appendix B: The asymptotic properties of β̂
It can be shown that S(β) has an unique solution at β̄ when model (1) is correctly speciﬁed.
Let the root of the estimating equation Sn (β) = 0 be denoted by β̂, β̂ converges to β̄ in
probability. Furthermore, one can show that

n

1/2

−1/2

Sn (β̄) = n

n
∑

κi + op (1)

i=1

where

κi = Xi

{

}
Yi − η (β̄ Xi ) −
−1

′

∫
0

τ

}
]
dMiC (u) [ {
Xi Yi − η −1 (β̄ ′ Xi ) − K(β̄, u) ,
G(u)
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and
[ {
}
]
K(β̄, u) = S(u)−1 E X Y − η −1 (β̄ ′ X) I(Y ≥ u) .
Coupled with the local linearity of the estimating function, this expansion implies that
n1/2 (β̂ − β̄) converges weakly to a mean zero Gaussian distribution with a variance-covariance
matrix of A−1 BA−1 , where
{
}
A = E X ⊗2 η̇ −1 (β̄ ′ X) ,
[
B=E X
∫

τ

+
0

⊗2

{
}2 ]
−1
′
Y − η (β̄ X)

[ {
}
]⊗2
dΛC (u)
E X Y − η −1 (β̄ ′ X) − K(β̄, u)
I(T ≥ u)
,
G(u)

η̇ −1 (·) is the derivative of η −1 (·) and a⊗2 = aa′ for vector a.
Furthermore, one can show that
n1/2 (β ∗ − β̂) = A−1 n1/2 S ∗ (β̂) + oP̃ (1) = n−1/2

n
∑

(Qi − 1)κ̂i + oP̃ (1)

i=1

where the probability measure P̃ is the product measure generated by {Q1 , . . . , Qn } and
data,
∫
{
}
−1
′
−1/2
κ̂i = Xi Yi − η (β̂ Xi ) − n

}
]
dM̂iC (u) [ {
Xi Yi − η −1 (β̂ ′ Xi ) − K̂(β̂, u) + op (1),
Ĝ(u)

τ

0

M̂iC (u) = I(Ui ≤ u)(1 − ∆i ) −

∫u
0

I(Ui ≥ t)dΛ̂C (t) and

∑n
K̂(β, u) =

i=1

Xi {Yi − η −1 (β ′ Xi )} I(Ui ≥ u)
∑n
.
i=1 I(Ui ≥ u)

Therefore, as n → ∞ the conditional variance of n1/2 (β ∗ − β̂) converges to
−1

−1

A (n

n
∑

κ̂i⊗2 )A−1 ,

i=1
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which is a consistent estimator of A−1 BA−1 .

ˆ
Appendix C: The Asymptotic Properties of ξ(v)
Let bh = b̃. As n → ∞, the estimating equation Sn (a, b̃; v) converges to
 [
] 
∫
−1
 ξ(v) − K(x)η̃ (a + b̃x)dx 
S(a, b̃; v) = fV (v) 
,
∫
− xK(x)η̃ −1 (a + b̃x)dx
where fV (·) is the density function of V. Since S(a, b̃; v) = 0 has an unique root (a, b̃) =
(η̃{ξ(v)}, 0), â → η̃{ξ(v)} and hb̂ → 0 in probability as n → ∞. Furthermore, by Taylor
series expansion, we have
(nh)1/2 {η̃ −1 (â) − ξ(v)}
n
˜i
[
]
n1/2 ∑ ∆
=
Kh (Vi − v) Yi − η̃ −1 {a0 + b0 (Vi − v)}
1/2
fV (v)h
i=1 Ĝ(t|v)
(
)
∫ ∞
n
h1/2 ∑
dMiC (u)
= 1/2
Kh (Vi − v){Yi − ξ(Vi )} −
Kh (Vi − v) [{Yi − ξ(Vi )} − R(u, v)] + op (1)
n
G(u)
0
i=1

where
R(u, v) =

γ1 (u|v)
ST (u|v)

and γj (u|v) = E[I(Y ≥ u){Y − ξ(v)}j |V = v].

Therefore, by martingale central limit theorem (nh)1/2 {η̃ −1 (â) − ξ(v)} converges weakly to
a mean zero Guassian with variance
[
ν2

∫
E[{Y − ξ(v)} |V = v] +
2

∞

{

0

where ν2 =

∫

γ1 (u|v)2
γ2 (u|v) −
ST (u|v)

}

]
dΛC (u)
,
G(u)

K(v)2 dv. If we use the KM estimator Ĝ(u) to replace Ĝ(u|v) in the estimating

˜
function Sn (a, b; v) and denote the corresponding estimator by ξ(v),
then one can similarly
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˜ − ξ(v)} is
show that the variance of the (nh)1/2 {ξ(v)
[
ν2

∫
E[{Y − ξ(v)} |V = v] +
2

0

∞

dΛC (u)
γ2 (u|v)
G(u)

]

ˆ − ξ(v)}.
which is greater than that of (nh)1/2 {ξ(v)
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Figure 1: Kaplan-Meier estimates of the survival functions of the two randomized groups
based on the ACTG 320 data
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Figure 2: Kaplan-Meier estimate of the overall patient survival function based on the PBC
data (Solid: point estimate, Dashed: 95% pointwise conﬁdence interval
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Figure 3: Estimated subject-speciﬁc restricted mean survival time (solid curve) over the
score, and its 95% pointwise (dashed curve) and simultaneous conﬁdence intervals (shaded
region). The dotted line is the 45 degree reference line. The survival function of the censoring
time C is estimated locally in the ﬁrst panel and based on the entire sample in the second
panel.
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Figure 4: Kaplan-Meier estimates of the survival functions of the four strata divided by
quartiles of the scores based on the PBC data
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Table 1: L1 prediction error estimates for the restricted mean event time up to 10 years of
the three model building procedures based on 100 random 5-fold cross-validations (CV)
L1 prediction error with CV
Cox model AFT model New model
5 covariates
2.34
2.00
1.94
16 covariates
2.34
2.11
2.10
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